產(chǎn)品描述
等級(jí)：活性藥物成分（API）
化學(xué)名稱(chēng):3 - (Cyclopropylmethoxy) 5、5-dimethyl-4 - (4 - (methylsulfonyl)苯基)furan-2——(5小時(shí))
分子式：C17H20O5S
分子量：336.403
規(guī)范：按照ChP/USP/EP建立企業(yè)標(biāo)準(zhǔn)
外觀:粉
總雜質(zhì)：不大于2.0%
純度：不低于98%
殘留溶劑：完全符合ICH Q3C要求
致突變雜質(zhì)：完全符合ICH M8
亞硝胺評(píng)估：可用
粒度：可根據(jù)客戶要求進(jìn)行普通級(jí)或研磨/篩分。
儲(chǔ)存方法：室溫
生產(chǎn)能力：商用
標(biāo)準(zhǔn)包裝：1kg/袋，5kg/袋，或根據(jù)客戶要求。
產(chǎn)品用途
Firocoxib是一種選擇性COX-2抑制劑（在離體貓血中，COX-2和COX-1的ic50分別為0.13和7.5 μM）。抑制lps誘導(dǎo)的前列腺素E2 （PGE2）的產(chǎn)生。在離體的狗、馬和貓全血中。Firocoxib分別以每天5 mg/kg和0.1 mg/kg的劑量給藥，可減少患有骨關(guān)節(jié)炎的狗和馬的跛行，誘導(dǎo)鎮(zhèn)痛，并改善活動(dòng)范圍。含有firocoxib的制劑已用于患有骨關(guān)節(jié)炎的狗和馬。
Firocoxib以Equioxx和Previcox等品牌銷(xiāo)售，是一種COX-2抑制劑（coxib）類(lèi)非甾體抗炎藥，批準(zhǔn)用于馬（Equioxx）和犬（Previcox）。Firocoxib是美國(guó)食品和藥物管理局批準(zhǔn)的第一個(gè)用于馬的COX-2抑制劑。Firocoxib不打算或批準(zhǔn)用于人類(lèi)醫(yī)學(xué)。
2004年7月，F(xiàn)irocoxib API在美國(guó)被批準(zhǔn)用于犬類(lèi)獸醫(yī)，2016年7月被批準(zhǔn)用于馬類(lèi)。Firocoxib是一種用于馬和狗的通用藥物。
聯(lián)系方式
四川青木制藥有限公司
四川省眉山市東坡區(qū)經(jīng)濟(jì)開(kāi)發(fā)區(qū)東區(qū)順江大道南段55號(hào)
國(guó)際營(yíng)銷(xiāo)部(International):
Email: sales@eastonpharma.cn
Tel: 028-87827187
國(guó)內(nèi)營(yíng)銷(xiāo)部(Mainland)：
李經(jīng)理 13880480517
楊經(jīng)理 15982276454
Product Description
Grade: Active Pharmaceutical Ingredient(API)
Chemical Name:3-(Cyclopropylmethoxy)-5,5-dimethyl-4-(4-(methylsulfonyl)phenyl)furan-2(5H)-one
Molecular Formula: C17H20O5S
Molecular Weight: 336.403
Specification: Enterprise Standard established according to ChP/USP/EP
Appearance: Powder
Total impurities: not more than 2.0%
Purity: not less than 98%
Residual Solvents: fully comply with ICH Q3C
Mutagenic impurities: fully comply with ICH M8
Nitrosamine assessment: available
Particle size: regular grade or milling/sieving according to customer’s requirement.
Storage: Room temperature
Production capacity: Commercial
Standard Package: 1kg/bag, 5kg/bag, or according to the customer’s requirement.
Applications
Firocoxib is a selective inhibitor of COX-2 (IC50s = 0.13 and 7.5 μM for COX-2 and COX-1, respectively, in isolated cat blood). It inhibits LPS-induced production of prostaglandin E2 (PGE2; ) in isolated dog, horse, and cat whole blood ex vivo. Firocoxib decreases lameness, induces analgesia, and improves range of motion in dogs and horses with osteoarthritis when administered at doses of 5 and 0.1 mg/kg per day, respectively. Formulations containing firocoxib have been used in dogs and horses with osteoarthritis.
Firocoxib sold under the brand names Equioxx and Previcox among others, is a nonsteroidal anti-inflammatory drug of the COX-2 inhibitor (coxib) class, approved for use in horses (Equioxx) and for use in dogs (Previcox). Firocoxib is the first COX-2 inhibitor approved by the U.S. Food and Drug Administration for horses. Firocoxib is not intended or approved for use in human medicine.
Firocoxib API was approved for veterinary use in the United States for dogs in July 2004 and for horses in July 2016. Firocoxib is available as a generic medication for horses and for dogs.
Contact Information
Sichuan Qingmu Pharmaceutical Co., Ltd.
Add: No. 55, South Shunjiang Avenue, East Economic Development Zone, Dongpo District, Meishan City, Sichuan, 620036, China
International Marketing Department:
Email: sales@eastonpharma.cn
Tel: 0086-28-87827187